Purpose Overexpression of HER2/neu in breast cancer is correlated with a poor prognosis. It may vary between primary tumors and metastatic lesions and change during the treatment. Therefore, there is a need for a new means to assess HER2/neu expression in vivo. In this work, we used 68 Ga-labeled DOTA-Z HER2:2891 -Affibody to monitor HER2/neu expression in a panel of breast cancer xenografts. Methods DOTA-Z HER2:2891 -Affibody molecules were labeled with 68 Ga. In vitro binding was characterized by a receptor saturation assay. Biodistribution and PET imaging studies were conducted in athymic nude mice bearing subcutaneous human breast cancer tumors with three different levels of HER2/neu expression. Nonspecific uptake was analyzed using non-HER2-specific Affibody molecules. Signal detected by PET was compared with ex vivo assessment of the tracer uptake and HER2/neu expression. Results The 68 Ga-DOTA-Z HER2:2891 -Affibody probe showed high binding affinity to MDA-MB-361 cells (K D = 1.4±0.19 nM). In vivo biodistribution and PET imaging studies demonstrated high radioactivity uptake in HER2/ neu-positive tumors. Tracer was eliminated quickly from the blood and normal tissues, resulting in high tumor-toblood ratios. The highest concentration of radioactivity in normal tissue was seen in the kidneys (227±14%ID/g). High-contrast PET images of HER2/neu-overexpressing tumors were recorded as soon as 1 h after tracer injection. A good correlation was observed between PET imaging, biodistribution estimates of tumor tracer concentration, and the receptor expression. Conclusion These results suggest that PET imaging using 68 Ga-DOTA-Z HER2:2891 -Affibody is sensitive enough to detect different levels of HER2/neu expression in vivo.
Introduction
The human epidermal growth factor receptor (HER2/neu; c-erbB2) is a 185-kDa glycoprotein with tyrosine kinase activity that plays an important role in regulating tumor cell survival, proliferation, maturation, and mobility [1] . It has also been shown to be involved in angiogenesis [2] . Amplification and/or overexpression of HER2/neu have been detected in approximately 20% of invasive breast carcinomas and in a significant fraction of ovary, lung, stomach, and bladder cancers. In breast cancer, HER2/neu overexpression is usually associated with increased tumor aggressiveness, resistance to therapies, high rates of recurrence, and increased mortality [3] .
HER2/neu expression is routinely determined by immunohistochemistry or fluorescence in situ hybridization at the time of diagnosis of the primary tumor. However, the HER2/neu status of the primary tumor does not always reflect that of metastatic lesions, and these expression levels might change during the course of treatment [4, 5] . Even though HER2/neu testing is common, there are problems associated with its sensitivity and specificity, potentially confounding the selection of appropriate patients for anti-HER2/neu therapy. Therefore, there is a need for methods that can assess global in vivo HER2/neu expression noninvasively and reproducibly. Molecular imaging modalities offer a strategy for determining HER2/neu expression and localizing HER2/neu-positive lesions in vivo, including inaccessible distant metastasis [6] .
Currently available HER2/neu-targeted ligands include full-length monoclonal antibodies, Fab fragments, F(ab′) 2 fragments, diabodies, minibodies, Affibody molecules, and peptides that can be labeled with either a contrast agent for magnetic resonance imaging (MRI), a fluorescent dye for optical imaging, positron-emitting radionuclides for positron emission tomography (PET), or gamma emitting radionuclides for single photon emission computed tomography (SPECT) [7, 8] . Among these, PET is the most sensitive human-scale diagnostic imaging modality, and provides the highest spatial resolution among radionuclide techniques especially when combined with CT. 68 Ga, a metallic positron emitter, is of particular interest for PET imaging since it can be obtained from a generator, thereby providing a convenient alternative to cyclotronproduced PET isotopes, such as 18 F and 124 I [9] . The stable oxidation state of gallium in aqueous solutions is +3 and it forms thermodynamically stable complexes with ligands containing oxygen, nitrogen, and sulfur donor atoms [9] . A variety of chelators have been developed to allow the formation of stable 68 Ga(+3) complexes. 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) is the most commonly used macrocyclic chelating agent for trivalent radiometals. Complexes of gallium with DOTA have been found to be stable in vivo and have been used in clinical studies [9, 10] .
The site-specific coupling of DOTA derivative during peptide synthesis provides a homogeneous conjugate with well-defined chemical and biological properties. 68 Ga also has attractive physical properties. Its decay is 89% by positron emission and 11% by electron capture. Its half-life (68 min) matches the pharmacokinetics of radiopharmaceuticals of low molecular weight (less than 60 kDa) that are most suitable for imaging applications due to their fast blood clearance, rapid diffusion and target localization [11] . A potential disadvantage of 68 Ga is the relatively high energy of the emitted positrons leading to a mean range in water of 2.9 mm that can reduce spatial resolution compared to PET images obtained with other potential positron labels, e.g. 18 F (mean range 0.6 mm) [12] .
Among all the HER2/neu-targeting agents, Affibody molecules seem to be the most promising tracers for imaging of HER2/neu receptor expression [13] . Affibody molecules were originally derived from the B-domain in the immunoglobulin-binding region of staphylococcal protein A. The B-domain is a relatively short peptide of 58 amino acids (6.5 kDa) that is folded into a three-helical bundle scaffold structure [14] .
Application of HER2/neu-specific Affibody molecules, labeled with a variety of radionuclides including 18 F, 64 Cu, 111 In, 90 Y, 177 Lu [14, 15] , and, lately, also 68 Ga, for diagnostic and therapeutic purposes have been widely investigated [16] . These studies have demonstrated high tumor to background ratio in HER2/neu imaging due to rapid blood clearance and high-affinity, tumor-specific targeting. In addition, our recent work has confirmed the potential of Affibody-based tracers for monitoring HER2/neu receptor changes in murine xenografts after therapeutic interventions [17] .
Here, we report the first imaging studies with 68
Ga-DOTA-Z HER2:2891 -Affibody probe in a panel of breast cancer xenografts with different HER2/neu expression levels as verified by flow cytometry and ELISA assay. Our results indicate that this tracer would enable noninvasive assessment of HER2/neu expression level in vivo by PET imaging. The radiochemical purity of the labeled conjugate was determined by reverse-phase high-performance liquid chromatography (RP-HPLC) (Beckmann-Coulter, System Gold) equipped with a UV166 detector (Beckmann Coulter, Brea, CA) using a C-18 column (Agilent Extend, C-18, 4.6× 150 mm), eluted with 0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile (solvent B). The HPLC gradient was 20-40% of solvent B over 16 min with a flow rate of 1 ml/min. Radioactivity was monitored during the HPLC run using an in-line radiodetector (Flow-Count radio-HPLC Detector System, Bioscan, Washington DC). The reaction mixture was then applied to a NAP-10 column (5-kDa cutoff), and eluted with phosphate-buffered saline (PBS) to obtain 68 Ga-DOTA-Z HER2:2891 . The purity of the filtrate was determined by RP-HPLC.
Material and methods

General
Cell lines
Human breast carcinoma cell lines (BT474, MDA-MB-361, and MCF7) that express different levels of HER2/neu were purchased from the American Type Culture Collection (Rockville, MD). The cells were cultured either in RPMI-1640 medium (BT474) or in Dulbecco's modified Eagle's medium (MCF7, MDA-MB-361) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (GIBCO) and penicillin/streptomycin (100 U/ml of each). Cells were grown as a monolayer at 37°C in a humidified atmosphere containing 5% CO 2 .
FACS analysis
For HER2/neu detection, cells were cultured overnight in T75 flasks (Sarstedt). The following day cells were rinsed twice with PBS and detached with a cell stripper (Cellgro). For every sample, 1 × 10 6 cells were collected, and incubated for 45 min on ice with anti-mouse Neu(24D2) fluorescein isothiocyanate monoclonal antibody or with IgG 1 fluorescein isothiocyanate mouse isotype control (Santa Cruz Biotechnology). After antibody staining, all cells were washed with PBS and resuspended in 0.3 ml of PBS for data acquisition.
All solutions were kept on ice. Flow cytometry was performed using a LSRII (BD Biosciences, San Jose, CA). FACSDiVa software (BD Biosciences) was used for data acquisition and FlowJo software for analysis (Tree Star). For each sample, 20,000 events were recorded, and the population corresponding to single cells was gated and analyzed as a histogram plot. Results are reported as mean fluorescence intensity.
ELISA The HER2/neu protein level in tissue lysates was measured according to a previously reported procedure [17] . Briefly, the tumor tissue was homogenized on ice using a Polytron homogenizer, and lysed in resuspension buffer provided with the ELISA kit (Calbiochem). Cell debris was removed through centrifugation of the suspensions at 13,000 rpm (4°C) for 15 min. The supernatants were collected and stored at −80°C. Before use, the protein concentration was estimated using a bicinchoninic acid assay kit (Pierce), according to the manufacturer's protocol. Then the HER2/neu protein level was measured using an ELISA kit, according to the manufacturer's recommended procedure.
Results are expressed in nanograms of HER2/neu per milligram of protein. The data are presented as the mean of two replicates, with each experiment repeated three times.
In vitro cell-binding assays
The in vitro binding characteristics of the 68 Ga-DOTA-Z HER2:2891 -Affibody was evaluated using saturation cellbinding assays. The day before the experiments, MDA-MB-361 cells were seeded in six-well plates at concentration of 5 × 10 5 cells per ml. For receptor saturation analysis, the cells were incubated (4°C, 2 h) with increasing concentrations (0.06-220 nM) of 68 Ga-DOTA-Z HER2:2891 -Affibody, either alone or with an additional 50-fold excess of nonlabeled Z HER2:2891 -Affibody molecules. Then the cells were washed with cold PBS (pH 7.0) and trypsinized, and the cell-associated radioactivity was measured using a γ-counter (1480 Wizard 3 automatic gamma counter; Perkin-Elmer, Waltham, MA). Specific binding was plotted against the total molar concentration of added 68 Ga-DOTA-Z HER2:2891 -Affibody. The K D value and the concentration of the tracer required to saturate the receptors (B max ) were determined by nonlinear regression using GraphPad Prism 5 (GraphPad Software, San Diego, CA). The B max value (nanomoles) was converted to the number of HER2/neu receptors per cell. The assay was performed in duplicate and repeated in two separate experiments. Biodistribution 68 Ga-DOTA-Z HER2:2891 -Affibody (3.7-6.7 MBq, 10-13 μg, 100 μl) was injected into the tail vein of mice bearing BT474 tumors. Mice were killed, and their major organs were dissected and weighed at 1 and 3 h after injection. Four mice were used for each data point. Radioactivity uptake in the tissues was measured, along with a standard of the injected dose, using a γ-counter. The results were expressed as percentage injected dose per gram of tissue (%ID/g).
To study the blood kinetics and the stability of 68 Ga-DOTA-Z HER2:2891 -Affibody in vivo, the blood was collected in vials containing 30 μl of heparin at 15, 30, 45, 60, 120, and 180 min after injection. The samples were weighed, and the radioactivity was measured by γ-counter. Then the blood was centrifuged (10 min at 10,000×g) and fractions of plasma (200-300 μl) were separated on NAP-10 columns. The mean concentrations of radioactivity in the blood (%ID/g) were plotted against time after injection, and the curve was fitted by a single exponential curve.
To confirm the specificity of 68 Ga-DOTA-Z HER2:2891 -Affibody binding in vivo, one group of mice bearing BT474 (very high HER2/neu expression) were injected with the non-HER2-specific Affibody molecules, His6-ZTaq-Cys-DOTA-68 Ga. The mice (n=4) were killed 1 h later, and their organs were analyzed as described above. This time-point was chosen since it showed the optimal tumor-to-background ratio for the binding of the labeled HER2-specific Affibody molecules.
PET/CT imaging PET scans were performed using the NIH Advanced Technology Laboratory Animal Scanner (ATLAS). CT images were obtained with the CT component of a Nano-SPECT/CT scanner from Bioscan (Bioscan, Washington, DC). Spatially registered and fused PET and CT images were obtained using a custom-designed adapter to the ATLAS bed support that allowed the Bioscan imaging bed (and the animals) to be reproducibly transferred between machines that had been previously calibrated for accurate spatial registration. The mice were anesthetized using isoflurane/O 2 (1.5-2.0% v/v), placed prone in the center of the field of view of the scanner, and injected with 68 Ga-DOTA-Z HER2:2891 -Affibody (3.7-6.7 MBq, 10-13 μg, 100 μl) via the lateral tail vein. Whole-body scanning was performed with a 2-cm axial field of view (three bed positions each of 10 min) at 1, 2 and 3 h after radiotracer injection and/or a 10-min emission scan (single field of view) was recorded 1 h after injection, both with a 100-to 700-keV energy window. The images were reconstructed with a two-dimensional ordered-subsets expectation maximum algorithm (2D-OSEM). No correction was applied for attenuation or scatter. For each scan, regions of interest (ROI) were manually drawn over the tumor and normal tissue. The maximum counts per pixel within the tumor or normal tissues were obtained from multiple ROIs (counts/s/ cm 3 ). The results were calculated as percentage injected dose per gram of tissue using a calibration constant obtained from scanning the 68 Ga source, assuming a tissue density of 1 g/ml, and dividing by the injected dose, decaycorrected to the time of scanning.
The CT component of the nanoSPECT/CT scanner was configured to acquire image data with the X-ray tube high voltage set to 65 keV, a sampling time of 1500 ms, and pixel size of 200 μm. The CT images were reconstructed using the fast cone beam FBP algorithm with a SheppLogan filter and a frequency cut-off at 100% of the Nyquist frequency. ATLAS and CT images were spatially registered and fused as described above.
Statistics
Statistical analysis was performed using GraphPad Prism 5. Correlations between PET quantification and biodistribution data were made using Pearson correlation test (p <0.05). A p-value less than 0.05 was considered significant. The elution profile of the 68 Ga-DOTA-Z HER2:2891 -Affibody reaction mixture showed a radiochemical purity exceeding 90% with the product eluting at a retention time of 7.2 min. The specific activity of the radiolabeled conjugate was in the range of 2.8-5.2 GBq/nmol. Uncomplexed 68 Ga eluted at 1.8 min. The elution profile of the purified 68 Ga-DOTA-Z HER2:2891 -Affibody showed the presence of a single peak (retention time of 7.2 min) corresponding to the isolated product (Fig. 1 ).
Results
HER2/neu expression
HER2/neu binding saturation
In vitro binding of 68 Ga-DOTA-Z HER2:2891 -Affibody to HER2/neu on MDA-MB-361 cells was investigated using a saturation binding assay. In a control experiment, a large excess of nonlabeled Affibody molecules was added in order to saturate HER2/neu receptors and demonstrate binding specificity. A representative saturation binding curve is shown in Fig. 2 . The data indicated a single class of high-affinity binding sites that had a mean K D value of 1.4 ± 0.19 nM. The B max value, expressed as the number of HER2/neu receptors per cell, was calculated to be (9.7 ± 0.02) × 10 5 .
Biodistribution
Uptake of 68 Ga-DOTA-Z HER2:2891 -Affibody in tumor and normal tissue of mice bearing tumors with very high HER2/ neu expression (BT474) 1 and 3 h after injection is shown in Table 2 . There was very high (31±2.1%ID/g) accumulation of radioactivity in the tumors as early as 1 h after injection. At that time, tumor-to-blood activity ratios were 27±4.4 and had increased to 91.8±13.7 3 h later.
Notably, the highest normal tissue concentration of radioactivity was seen in the kidneys. The uptake ranged from 223±26%ID/g to 227%±14.2 ID/g. The tracer uptake in all other organs was low over the entire time-course of the experiment.
The in vivo HER2/neu binding specificity was evaluated using non-HER2-specific Affibody molecules. The tumorassociated radioactivity 1 h after injection in mice bearing BT474 tumors was comparable to that of surrounding tissues: 1.1±0.4%ID/g in the tumor, 1.3±0.2%ID/g in the liver and 0.2±0.1%ID/g in the muscles. Notably, the tumor uptake was 31-fold lower than observed in mice receiving the HER2/neu-specific 68 Ga-DOTA-Z HER2:2891 -Affibody. This difference confirmed that the tracer accumulation in these tumors was HER2/neu-dependent. 
Blood kinetics
The mean radioactivity in the blood as a function of time after administration of 68 Ga-DOTA-Z HER2:2891 -Affibody is shown in Fig. 3 . The serum clearance was rapid with an elimination half-life of 20.8 min. The metabolic stability of 68 Ga-labeled Affibody in blood plasma was also evaluated. To distinguish radiolabeled Affibody (high molecular weight) from small-molecule metabolites (low molecular weight), plasma samples were eluted through NAP-10 columns (5-kDa cut-off) with PBS. Reference analysis of a solution containing 68 Ga-DOTA-Z HER2:2891 -Affibody molecules on the NAP-10 column resulted in 97% of the radioactivity eluted in the high molecular weight fractions. The majority of radioactivity from plasma samples was also associated with the high molecular weight fractions, indicating that the tracer was still present in the blood 2 h after injection (Fig. 3) .
PET/CT imaging
A representative PET/CT whole-body image of a mouse bearing a BT474 tumor obtained 2 h after tracer injection is shown in Fig. 4 . Axial sections comparing mice with different levels of HER2/neu expression are shown in Fig. 5 .
High contrast images were recorded 1 h after injection and indicated high tracer uptake in tumors expressing high (BT474) and medium (MDA-MB-361) levels of HER2/neu as compared with the low-expressing tumors (MCF7). The radioactivity uptake in the tumors was significantly higher than in normal tissues except for the kidneys. The ROI values ranged from 31±7.0%ID/g for BT474 to 18.8±2.5%ID/g for MDA-MB-361. Poor, but still detectable, signal was observed from MCF7 tumors (the ROI value was 3.2±0.4%ID/g). Notably, we found a strong and significant correlation between %ID/g values obtained from biodistribution and PET quantification studies (R 2 =0.94, p<0.0001) in all tumor-bearing mice (Fig. 6a) . Both tracer accumulation and the signal detected in tumor by PET depended on the receptor expression, as assessed by ELISA (Fig. 6b) .
Discussion
Molecular imaging has great potential for characterization of therapeutically important targets in malignancies [19] , including HER2/neu [6, 20] . Because HER2/neu expression levels in metastases may be quite different from the levels in primary tumor [21] , assessment of the specific expression of these receptors on cancer cells in various locations may be useful in selecting appropriate therapy [22] .
However, the development of HER2/neu-specific imaging probes for routine clinical use has not yet been successful.
In our previous work [15] , we labeled Affibody molecules with 18 F, which is widely available and a nearly pure (97%) positron emitter with a relatively short, but clinically useful, half-life of 110 min. However, 18 F production requires a cyclotron, and the radiolabeling procedures involving this radionuclide require several low-yielding steps that are often time consuming. Therefore, in this study, we evaluated the potential of 68 Ga-DOTA-Z HER2:2891 -Affibody [23] as an imaging agent in xenografts with different HER2/neu expression levels. 68 Ga presents an attractive alternative as a radionuclide for PET imaging. It can be obtained from commercially available 68 Ge/ 68 Ga generators, which have a half-life of 271 days and thus can provide an almost constant supply of 68 Ga for over 1 year. The labeling procedures are wellestablished and relatively straightforward. Also, the unit cost of 68 Ga from generators is reasonable when amortized over a year, which makes it even more attractive for busy nuclear medicine departments, particularly those with limited or no access to a cyclotron.
Most of the efforts in developing tracers for HER2/neu have focused on using anti-HER2/neu antibodies. However, antibodies are rather bulky proteins typically characterized by limited tumor penetration and slow clearance from the circulation. A successful molecular imaging probe requires high affinity and specificity in binding to tumor-associated structures with minimal nonspecific accumulation in normal tissues and rapid clearance from the background. Optimally, it should easily penetrate the tumor parenchyma and rapidly clear from the blood to increase the tumor to background ratio. Recently, significant progress has been made in TUMOR KIDNEY Estrogen Pellet Fig. 4 Posterior whole-body fusion PET/CT image acquired 2 h after tracer injection of a representative athymic mouse implanted subcutaneously in the right shoulder with BT474 breast cancer cells Ga in a mouse bearing a BT474 tumor protein display technology that has led to the discovery of many small proteins and peptides [24, 25] . Among them, Affibody molecules have been shown to meet most of the aforementioned requirements providing a suitable platform for the development of new imaging probes [14, 26] .
Our current results demonstrated the high affinity of 68 Ga-DOTA-Z HER2:2891 -Affibody for HER2/neu receptors on MDA-MB-361 cells in vitro. The K D was similar to those found with other Affibody radioconjugates and was comparable to those of antibodies used clinically for imaging and therapy (e.g., the reported affinity of trastuzumab to HER2/neu is 5 nM) [27] .
The in vivo pharmacokinetics data were also promising. The elimination half-life estimated by measuring radioactivity in blood samples at several time points after injection was approximately 21 min. This relatively fast clearance, combined with lack of radioactivity in the low molecular weight fraction of serum incubated with the tracer ex vivo (data not shown) indicate that the conjugate was stable in vivo as the transchelation of free 68 Ga to transferrin, which would extend its circulation time, did not occur. It also resulted in high tumor-to-blood ratios and high-contrast PET images of 68 Ga-DOTA-Z HER2:2891 -Affibody molecules in the tumor as early as 1 hour after tracer injection. It is noteworthy that the obtained tumor-to-blood ratios were higher than for other imaging probes including 68 Ga-DOTA-MUT-DS, 68 Ga-ABY-002, 68 Ga-labeled DOTA-F (ab′) 2 fragment of Herceptin, as well as full-length antibodies and antibody fragments labeled with 124 I, 89 Zr and, 86 Y [28] [29] [30] [31] .
Because of the fast blood clearance, the images showed high tumor accumulation as compared with other tissues (except the kidneys) in tumors expressing high and intermediate levels of HER2/neu. In BT474 tumors expressing high levels of HER2/neu the uptake reached 31±7.0%ID/g as early as 1 h after tracer injection, and the level was higher than the accumulation levels recently reported by Ren et al. [30] and Tolmachev et al. [16] for SKOV3 tumors. The absolute tumor accumulation reported by these authors was only 4.12±2.2%ID/g (2 h after injection of an Affibody-based, two-helix 68 Ga-DOTA-MUT-DS molecule) and 8.9±1.0%ID/g (45 min after injection of 68 Ga-ABY-002). It should be noted that SKOV3 cells express even more HER2/neu receptors than BT474 (ELISA results from our laboratory: 335 ng/mg for SKOV3 versus 260 ng/mg for BT474). These results are in line with our previous data obtained with a radiofluorinated probe [17] . It should be stressed that correction for the uptake for nonspecific binding of His6-ZTaq-Cys-DOTA- 68 Ga was not necessary since the accumulation of this non-HER2-specific tracer was approximately at the same level as that in surrounding tissues, and the tumors were not detectable.
We have previously shown a strong association between the uptake of 18 F-FBEM-Z HER2:342 -Affibody tracer in a panel of breast cancer tumor xenografts with different HER2/neu expression [17] . Also, McLarty et al., using mice bearing tumors with a wide range of receptor levels, showed a correlation between 111 In-DTPA-trastuzumab accumulation and HER2/neu density in individual tumors [32] .
In this work, we investigated the correlation between HER2/neu expression determined by PET imaging in vivo and the biodistribution data for each particular tumor model following injection of 68 Ga-DOTA-Z HER2:2891 -Affibody and by comparison to HER2/neu protein concentration measured in the same tumors ex vivo by ELISA. Based on our experience with 18 F-labeled Affibody molecules and considering the short half-life of 68 Ga, the biodistribution and imaging studies were done at 1 and 3 h after tracer injection. There was no indication of label instability since the tracer was rapidly cleared from the blood and liver. By analyzing the biodistribution and imaging data, we were also able to correlate the tracer uptake with number of HER2/neu receptors. Unlike results reported for antibodies by McLarty et al. [32] , who had to apply appropriate corrections for nonspecific tumor uptake and blood flow, we found a strong linear correlation between PET values (%ID/g) and biodistribution data that also corresponded to the HER2/neu level in each tumor as assessed by ELISA. However, this dependence was not linear due to many factors that might have affected the relationship between the data obtained by these two methods. For instance, ELISA measures the total HER2/neu level, while the PET signal reflects only the levels of extracellular domain of HER2/neu present in the tissue, which may have contributed to the lack of linear correlation. Also tumor vascularization and the specific activity of the tracers might disturb the linear dependence of these variables. Therefore, we do not claim that there is a statistically significant correlation between the in vivo measured PET signal and ex vivo ELISA data. Instead, we conclude that there is a trend, and it is clear that the PET signal depends on the receptor expression, although the current data are not sufficient to provide the exact numerical function describing this relationship.
In addition, it is important to note that using galliumlabeled agents the estimation of receptor expression may be limited for tumors expressing very low receptor levels. This is due to the greater positron range of 68 Ga (1.9 MeV) compared for example to that of 18 F, which could lead to poorer spatial resolution and erroneous assignment of the ROI. The intrinsic resolution of small-animal PET scanners has improved to a level where the positron range of the radionuclide eventually could influence the effective spatial resolution. van Dalen et al. showed that the image resolution of a PET scanner with a 1.5-mm intrinsic system resolution is decreased by using PET emitters with large positron ranges such as 68 Ga and 124 I [33] . This could affect: (1) the detection of small lesions, (2) the assessment of low receptor expression, (3) the ability to distinguish lesions that are close together, and (4) quantification of tumor uptake. Therefore, the positron energy and range must be considered when planning small-animal imaging. On the other hand, from a clinical point of view, Yang et al. demonstrated that the conventional FWHM of 18 F and of 68 Ga are indistinguishable in soft tissues (3.01 mm vs. 3.09 mm) [34] . This implies that with the spatial resolution of 5-7 mm for current clinical scanners, image quality using 68 Ga-labeled tracers should be comparable to that using 18 F-labeled agents.
We observed very high radioactivity accumulation in the kidney. These values are comparable to those previously reported for 68 Ga-labeled Affibody molecules [16] . The use of 68 Ga as well as other metal positron emitters including 64 Cu and 89 Zr leads to residualization that results in trapping of radionuclides in lysosomes after internalization and degradation of the tracer [35, 36] . Because of this phenomenon, the kidney is the major dose-limiting organ for this tracer. However, this is not a major diagnostic limitation since renal lesions are uncommon in breast cancer. Positively charged amino acids, such as lysine and arginine are now commonly used for renal protection in clinical trials of peptide receptor-targeted radionuclide therapy, and may be useful in this setting as well [37] . Studies of the possible effect of positively charged amino acids on accumulation of radioactivity in the kidney following 68 Ga-DOTA-Z HER2:2891 -Affibody administration are, however, outside the scope of this paper.
In conclusion, our results indicate that differences in HER2/neu expression levels can be detected in vivo by PET imaging with 68 Ga-DOTA-Z HER2:2891 -Affibody. This generator-produced agent may, therefore, be useful in the characterization HER2/neu-positive tumors as an alternative to 18 F-labeled compounds especially where access to a cyclotron is limited.
